1
PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
Condition(s): Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer Last Updated: August 1, 2012Terminated
305 Clinical Trials for: “Reaferon”, Page 1 of 16
Hide Studies Not Seeking New Volunteers
2
Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders
Condition(s): Chronic Hepatitis C Last Updated: March 10, 2011Completed
3
Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)
Condition(s): Hepatitis C, Chronic; Hepatitis C Last Updated: August 28, 2009Terminated
4
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron
Condition(s): Leukemia, Myeloid, Philadelphia-Positive Last Updated: July 31, 2012Terminated
5
Nordic Adjuvant IFN Melanoma Trial
Condition(s): Melanoma; Adjuvant Therapy Last Updated: December 13, 2010Completed
6
PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML
Condition(s): Chronic Myeloid Leukemia Last Updated: August 24, 2012Active, not recruiting
7
Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685AM3)(COMPLETED)
Condition(s): Hepatitis C, Chronic Last Updated: October 28, 2009Completed
8
Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600 AM2)
Condition(s): Melanoma Last Updated: December 11, 2012Completed
9
Zidovudine, Interferon Alfa-2b, and PEG-Interferon Alfa-2b in Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma
Condition(s): Lymphoma; Precancerous/Nonmalignant Condition Last Updated: February 8, 2013Active, not recruiting
10
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
Condition(s): Renal Cell Carcinoma Last Updated: November 22, 2011Terminated
11
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery
Condition(s): Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma Last Updated: April 29, 2013Recruiting
12
Study to Evaluate Sodium Stibogluconate With Interferon Alpha-2b
Condition(s): Advanced Cancer; Solid Tumors Last Updated: November 23, 2011Withdrawn
13
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
Condition(s): Advanced Cancer; Solid Tumors Last Updated: November 21, 2011Completed
14
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC
Condition(s): Hepatitis C Last Updated: February 13, 2012Completed
15
Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)
Condition(s): Hepatitis C, Chronic Last Updated: July 28, 2011Completed
16
Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
Condition(s): Metastatic Gastrointestinal Carcinoid Tumor; Recurrent Gastrointestinal Carcinoid Tumor; Regional Gastrointestinal Carcinoid Tumor Last Updated: January 22, 2013Completed
17
Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery
Condition(s): Recurrent Melanoma; Recurrent Renal Cell Cancer; Stage III Melanoma; Stage IV Melanoma; Stage IV Renal Cell Cancer Last Updated: May 1, 2013Completed
18
Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C
Condition(s): Hepatitis C Last Updated: February 1, 2012Completed
19
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma
Condition(s): Stage IA Skin Melanoma; Stage IB Skin Melanoma; Stage IIA Skin Melanoma; Stage IIB Skin Melanoma; Stage IIC Skin Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma Last Updated: November 7, 2012Active, not recruiting
20
Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia
Condition(s): Anemia; Liver Disease; Hypoxemia Last Updated: February 19, 2013Terminated
